Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-58
Closed -$2.46K 764
2024
Q2
$2.46K Hold
58
﹤0.01% 832
2024
Q1
$2.58K Buy
+58
New +$2.64K ﹤0.01% 816
2023
Q4
Sell
-58
Closed -$2.51K 729
2023
Q3
$2.51K Hold
58
﹤0.01% 787
2023
Q2
$3K Hold
58
﹤0.01% 769
2023
Q1
$3K Hold
58
﹤0.01% 779
2022
Q4
$3K Hold
58
﹤0.01% 749
2022
Q3
$3K Hold
58
﹤0.01% 764
2022
Q2
$3K Hold
58
﹤0.01% 770
2022
Q1
$3K Hold
58
﹤0.01% 814
2021
Q4
$3K Hold
58
﹤0.01% 839
2021
Q3
$3K Hold
58
﹤0.01% 827
2021
Q2
$3K Hold
58
﹤0.01% 831
2021
Q1
$3K Hold
58
﹤0.01% 827
2020
Q4
$3K Hold
58
﹤0.01% 786
2020
Q3
$3K Hold
58
﹤0.01% 784
2020
Q2
$3K Hold
58
﹤0.01% 785
2020
Q1
$3K Hold
58
﹤0.01% 757
2019
Q4
$2K Hold
58
﹤0.01% 797
2019
Q3
$2K Hold
58
﹤0.01% 800
2019
Q2
$3K Hold
58
﹤0.01% 763
2019
Q1
$3K Sell
58
-128
-69% -$5.15K ﹤0.01% 762
2018
Q4
$7K Sell
186
-149
-44% -$5.53K 0.01% 478
2018
Q3
$12 Sell
335
-1
-0.3% -$40 0.01% 396
2018
Q2
$13 Hold
336
0.01% 409
2018
Q1
$12K Sell
336
-4
-1% -$140 0.01% 416
2017
Q4
$11K Buy
+340
New +$11.7K 0.01% 426

Other funds holding QGEN

Front Row Advisors's QGEN Position: Q3 2024 in Review

Front Row Advisors sold out of Qiagen (QGEN) in Q3 2024, closing a stake of 58 shares — an estimated $2.46K sold.

Front Row Advisors first reported a position in QGEN in Q4 2017 and held it in 26 quarters. The position peaked at $12K in Q1 2018. 329 funds tracked by Wall St. Rank hold QGEN as of Q3 2024.

  • Front Row Advisors reported no remaining Qiagen position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 58 Qiagen shares in Q3 2024, an estimated $2.46K.
  • Front Row Advisors first reported a position in Qiagen in Q4 2017 and held it in 26 quarters.
  • Front Row Advisors's Qiagen position peaked at $12K in Q1 2018.
  • 329 funds tracked by Wall St. Rank held Qiagen as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.